Benitec to sell 1,875,000 American Depositary Shares through its IPO

Bookrunner BMO, lead manager Maxim and co-manager Roth Capital assist

By Devika Patel

Knoxville, Tenn., Aug. 10 – Benitec Biopharma Ltd. will sell 1,875,000 American Depositary Shares in its initial public offering with warrants to purchase 525,000 ADSs and a 45-day greenshoe of 281,250 additional ADS and 78,750 ADS warrants, according to a Form F-1/A filed Monday with the Securities and Exchange Commission. The company has registered up to $37,404,037of underlying ordinary stock for the deal, which was announced on July 27.

Each ADS is being sold together with 0.28 five-year warrants, which will be exercisable at the same price as the price-per-ADS. Each ADS represents 20 ordinary shares.

Maxim Group LLC is the bookrunner.

Proceeds will be used for clinical trials, development, preclinical studies, working capital, research and general corporate purposes.

The biotechnology company is based in Balmain, New South Wales, Australia. The company has applied to list the ADSs on the Nasdaq under the symbol “BNTC.”

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.